Table 4.

The characteristics of patients with COVID-19 according to their disease symptoms

CharacteristicsAsymptomatic (n=28)Symptomatic (n=103)P Value
Age (yr), mean (SD)62.1 (15.4)63.7 (12.6)0.58
Sex (n, %)0.66
Male15 (53.6)60 (58.3)
Female13 (46.4)43 (41.8)
Primary causes of ESKD, n (%)
Diabetic nephropathy3 (10.7)32 (31.1)0.03
Hypertensive kidney disease4 (14.30)30 (29.1)0.11
GN4 (14.3)21 (20.4)0.47
Polycystic kidney disease1 (3.6)3 (2.9)0.99a
Lupus nephritis2 (7.1)2 (1.9)0.20a
Others14 (50.0)15 (14.6)<0.001
Coexisting disorder, n (%)
Cardiovascular disease17 (60.7)73 (70.9)0.30
Diabetes mellitus1 (3.6)29 (28.2)0.006
Chronic obstructive pulmonary disease1 (3.6)4 (3.9)0.99a
Cancer1 (3.6)1 (1.0)0.38a
Hepatitis B infection2 (7.1)9 (8.7)0.99a
Hepatitis C infection1 (3.6)2 (1.9)0.52a
Laboratory findings, median (IQR)
Hemoglobin (g/L)110.0 (91.0–121.0)104 (90.0–117.4)0.24b
PLT (109/L)151.5 (108.9–191.0)138.5 (105.0–185.5)0.80b
White blood cells (109/L)5.3 (3.5–7.9)5.0 (4.0–7.3)0.82b
Lymphocytes (109/L)1.0 (0.8–1.3)0.7 (0.4–1.0)0.008b
Neutrophils (109/L)4.0 (2.6–6.4)3.9 (3.0–6.1)0.93b
Previous medication, n (%)
ACEI/ARB4 (14.3)41 (40.2)0.01
Immunosuppressant3 (10.7)4 (3.9)0.17a
  • P values were calculated by the t test or Wilcoxon test for continuous variables, and the chi-squared test for categorical variables, otherwise Fisher’s exact test was used when the data were limited. ACEI/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker.

  • a P values from Fisher’s exact test.

  • b P values from the Wilcoxon test.